Skip to main content

Advertisement

Table 2 The number of positive bone marrow (BM) samples shown separately for the three mRNA markers mammaglobin A (hMAM), cytokeratin 19 (CK19) and TWIST1, as well as in combination by construction of a multimarker panel

From: Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome

 BM samples  No. of   patientsMissing   data  Marker expression   Multimarker   positive* 
 hMAM   CK19   TWIST1 
BM1 154 0 4 (3) 14 (8) 5 (2) 21 (11)
BM2 144 10 6 (5) 5 (2) 9 (4) 17 (8)
BM3 109 45 6 (3) 1 (1) 2 (1) 7 (3)
BM2 and/or BM3 154 0 11 (7) 5 (2) 11 (5) 23 (10)
  1. BM1 drawn prior to surgery; BM2 drawn three weeks after primary surgery; BM3 drawn six months after primary surgery.
  2. The number of systemic relapse is shown in parentheses.
  3. *Positive for at least one of the markers hMAM, CK19 and TWIST1.